Edition:
United States

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

3.46USD
22 Jun 2018
Change (% chg)

$0.12 (+3.59%)
Prev Close
$3.34
Open
$3.34
Day's High
$3.47
Day's Low
$3.30
Volume
15,454
Avg. Vol
9,273
52-wk High
$5.25
52-wk Low
$2.25

Chart for

About

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.... (more)

Overall

Beta: --
Market Cap(Mil.): $58.00
Shares Outstanding(Mil.): 16.76
Dividend: --
Yield (%): --

Financials

  AZRX.OQ Industry Sector
P/E (TTM): -- 29.56 34.14
EPS (TTM): -1.05 -- --
ROI: -458.50 13.56 13.10
ROE: -927.80 15.35 15.09

BRIEF-Azurrx Biopharma Enrolls New Patients For Phase IIA Study Of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES ENROLLMENT OF THREE NEW PATIENTS FOR ITS PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:

Feb 12 2018

BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY

Jan 18 2018

BRIEF-AzurRx Biopharma receives $2 mln in proceeds from exercise of warrants

* AZURRX BIOPHARMA RECEIVES $2 MILLION IN PROCEEDS FROM EXERCISE OF WARRANTS

Jan 16 2018

Earnings vs. Estimates